Melanoma

Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesPhio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Raised approximately $12.08 million in gross proceeds since beginning of December 2024 Proceeds intended to be directed for development costs…

4 months ago
Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain SarcomasSonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid tumors, enters…

4 months ago
Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced MelanomaReplimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma

Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma

PDUFA action date of July 22, 2025, with priority reviewWOBURN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:…

4 months ago
Junshi Biosciences Announces Commercialization Partnership with LEO Pharma for Toripalimab in EuropeJunshi Biosciences Announces Commercialization Partnership with LEO Pharma for Toripalimab in Europe

Junshi Biosciences Announces Commercialization Partnership with LEO Pharma for Toripalimab in Europe

SHANGHAI, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading…

4 months ago
Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesPhio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - January 16, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics…

4 months ago
BioWorld by Clarivate Releases Comprehensive 2024 Year in ReviewBioWorld by Clarivate Releases Comprehensive 2024 Year in Review

BioWorld by Clarivate Releases Comprehensive 2024 Year in Review

Series Recaps Biopharma, MedTech, and Science Trends and Breakthroughs That Shaped the Year LONDON, Jan. 16, 2025 /PRNewswire/ -- BioWorld™…

4 months ago
Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesPhio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - January 15, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics…

4 months ago
Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesPhio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - January 14, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics…

4 months ago
Sona Nanotech’s THT Cancer Therapy Preclinical Efficacy Studies Published In Peer-Reviewed Scientific JournalSona Nanotech’s THT Cancer Therapy Preclinical Efficacy Studies Published In Peer-Reviewed Scientific Journal

Sona Nanotech’s THT Cancer Therapy Preclinical Efficacy Studies Published In Peer-Reviewed Scientific Journal

Halifax, Nova Scotia--(Newsfile Corp. - January 13, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is…

4 months ago